Welcome to our dedicated page for Palisade Bio SEC filings (Ticker: PALI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Palisade Bio, Inc. (Nasdaq: PALI) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-assisted summaries to help interpret complex documents. As a clinical-stage biopharmaceutical company focused on autoimmune, inflammatory, and fibrotic diseases, Palisade Bio uses SEC filings to describe its development of once-daily, oral PDE4 inhibitor prodrugs, capital-raising activities, and corporate governance matters.
Through registration statements such as Form S‑1, investors can review detailed information about Palisade Bio’s business, risk factors, and public offerings of common stock and pre-funded warrants. These documents outline how the company intends to finance its clinical programs, including the advancement of its lead candidate PALI-2108 for ulcerative colitis and fibrostenotic Crohn’s disease. AI tools on this page can highlight key sections, such as use of proceeds, dilution, and summary business descriptions.
Current reports on Form 8‑K provide timely updates on material events. Recent 8‑Ks discuss topics such as Nasdaq minimum bid price compliance, the adoption and later termination of a Phantom Unit Plan for executives and directors, outcomes of annual meetings of stockholders, and the approval of a reverse stock split authorization within a specified ratio range. These filings also cover voting results, equity-based compensation arrangements, and other corporate actions relevant to shareholders.
Proxy statements on Schedule 14A offer further detail on director elections, auditor ratification, capital structure proposals, and special meeting agendas, including warrant-related share issuance approvals. On Stock Titan, AI-powered analysis can help users quickly identify the portions of these filings that address governance changes, executive arrangements, and share authorization requests. Together, the real-time feed of SEC documents and AI summaries enables a structured view of how Palisade Bio manages its capital structure, listing status, and development priorities for its gut-targeted PDE4 inhibitor prodrug platform.
Palisade Bio, Inc. received a new large shareholder disclosure from Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia. The group reports beneficial ownership of 9,567,898 shares of Palisade Bio common stock, representing 6.4% of the outstanding class.
The ownership is held through Octagon Investments Master Fund, with Octagon acting as investment manager and Ting Jia as the control person of Octagon. The filing states the securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Palisade Bio.
Palisade Bio, Inc. received a Schedule 13G from Franklin Resources affiliates reporting a passive ownership position in its common stock. As of December 31, 2025, Franklin Advisers, Inc. is reported as having sole voting and dispositive power over 9,163,990 shares of common stock, representing 6.0% of the class. This total includes 4,071,428 shares issuable upon exercise of warrants.
The securities are held for investment management clients of Franklin Resources’ investment management subsidiaries, which have the right to receive dividends and sale proceeds. Charles B. Johnson and Rupert H. Johnson, Jr. are included as reporting persons but each reports beneficial ownership of 0 shares and the filing states that Franklin Resources, the principal shareholders and subsidiaries disclaim pecuniary interest and beneficial ownership beyond what is required for reporting. The filers certify the holdings are in the ordinary course of business and not for changing or influencing control of Palisade Bio.
Palisade Bio director Donald Allen Williams reported a purchase of company stock. On January 16, 2026, he bought 5,000 shares of common stock at a price of $1.6712 per share, increasing his direct holdings to 10,728 shares.
In addition to his direct ownership, the filing shows an indirect holding of 3,000 common shares through the reporting person's defined benefit plan. This Form 4 reflects insider activity by a company director, providing transparency about changes in his ownership stake.
Palisade Bio, Inc. director Donald Allen Williams reported buying 5,000 shares of common stock on January 9, 2026 at a price of $1.88 per share. After this open-market purchase, he directly owns 5,728 common shares and has an additional 3,000 shares reported as indirectly owned through the reporting person's defined benefit plan.
Palisade Bio, Inc. filed a Form S-8 registering 236,557 shares of common stock for issuance to employees, directors, contractors, and consultants under its 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan. The filing uses General Instruction E to add shares to previously registered plan securities and, under Rule 429, a combined prospectus will cover these and prior plan registrations.
As context, the company previously registered an aggregate 129,259 shares for the same plans across earlier S-8 filings. All share amounts in this filing reflect the 1-for-50 reverse split effective November 16, 2022 and the 1-for-15 reverse split effective April 5, 2024.
Palisade Bio (PALI) reported Q3 2025 results, highlighting lower operating spend and a major post‑quarter financing that strengthened liquidity. Operating expenses fell to $2.9 million from $3.6 million a year ago as research and development declined to $1.4 million, while general and administrative was $1.5 million.
The company posted a Q3 net loss of $2.9 million and a nine‑month net loss of $7.9 million. Cash and cash equivalents were $5.2 million at September 30, 2025, down from $9.8 million at year‑end, with net cash used in operations of $7.7 million for the nine months. Total assets were $7.0 million and stockholders’ equity was $3.2 million.
After quarter‑end, Palisade closed an underwritten equity offering on October 2, 2025 for $138 million in gross proceeds. Management concluded this significantly increases working capital and removes substantial doubt about continuing as a going concern for one year from issuance of these financial statements. During Q3, a July warrant‑exercise inducement brought in $3.9 million gross and created 8.64 million replacement warrants. Shares outstanding were 149,003,210 as of November 5, 2025; 9,119,152 shares were outstanding as of September 30, 2025.
Palisade Bio, Inc. (PALI) filed an amended Form 4 reporting a corrected equity award to a director. On 10/06/2025, the reporting person acquired 182,000 Restricted Stock Units (RSUs) at $0, with 182,000 derivative securities beneficially owned directly after the transaction.
The amendment corrects a previously reported grant of 1,538,700 RSUs; the issuer has rescinded 1,356,700 of that prior amount. Each RSU represents a right to receive one share of common stock; until sufficient shares are reserved under the 2021 Equity Incentive Plan, RSUs may be settled in cash upon vesting.
The RSUs vest in three equal annual installments, with the first installment vesting on the earlier of the 2026 annual meeting of stockholders or the anniversary of October 6, 2025, subject to continuous service.
Palisade Bio (PALI) filed a Form 4/A amending a director equity award. The company corrected a previously reported grant, stating that the award is 60,600 RSUs after the issuer rescinded 450,100 RSUs from an initially reported 510,700 RSUs on 10/06/2025.
Each RSU represents a right to one common share, though settlement may be in cash until sufficient shares are reserved under the 2021 Equity Incentive Plan. The RSUs vest in three equal annual installments, with the first vesting on the earlier of the 2026 annual meeting of stockholders or the anniversary of October 6, 2025, contingent on continued service.
Palisade Bio (PALI) filed a Form 4/A amending a prior equity grant for a director. The filing reports 60,600 restricted stock units (RSUs) granted on October 6, 2025, shown at a derivative security price of $0 with 60,600 derivative securities beneficially owned on a direct basis.
The amendment corrects a previously reported grant of 510,700 RSUs; the issuer has rescinded 450,100 of those RSUs. Each RSU represents a contingent right to one share, though RSUs may be settled in cash until sufficient shares are reserved under the 2021 Equity Incentive Plan. The RSUs vest in three equal annual installments, with the first vesting on the earlier of the 2026 annual meeting of stockholders or the anniversary of October 6, 2025, subject to continuous service.
Palisade Bio (PALI) reported a compensation plan change. The Board adopted a Phantom Unit Plan on September 4, 2025, and later approved its termination effective October 22, 2025.
Phantom Units granted under the plan to Chief Executive Officer J.D. Finley, Chief Medical Officer Mitchell Jones, and Senior Vice President of Finance Ryker Willie were unvested as of the termination date and will terminate for no consideration.